Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine - Wikidata - awgldk - TriplyDB

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

http://www.wikidata.org/entity/Q33434415

about

High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon Current ebola vaccines Emerging targets and novel approaches to Ebola virus prophylaxis and treatment Ebola virus vaccines: an overview of current approaches Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin Ebola and Marburg virus vaccines.Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice Development of adenoviral vector-based mucosal vaccine against influenza.Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana.Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus.A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice DNA vaccines for biodefense.Mechanisms of immunity in post-exposure vaccination against Ebola virus infection.Filovirus vaccines.Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.Progress in filovirus vaccine development: evaluating the potential for clinical use.DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model.Potential vaccines and post-exposure treatments for filovirus infections.Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents.Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection.Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus.Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.Characterization of host immune responses in Ebola virus infections.Adenovirus-vectored Ebola vaccines.Fc receptors in antibody-dependent enhancement of viral infections.Future Prospects for the Development of Cost-Effective Adenovirus Vaccines.Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro.Characterization of the RNA silencing suppression activity of the Ebola virus VP35 protein in plants and mammalian cells Adenoviral type 35 and 26 vectors with a bidirectional expression cassette in the E1 region show an improved genetic stability profile and potent transgene-specific immune response.Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.

P2860

Q21090030-1492000A-FB41-48F4-8BA3-988F9DF30677 Q21534720-E33ED061-7086-4F51-B18F-6C2DAA59B4F9 Q24597625-D7856C3B-A5A4-48FA-AECA-983738D56ACC Q26999232-51089CB1-01C5-49BC-846F-5B71CEE60484 Q28731982-A47DA408-5AD5-429D-87C1-A63104D75D6F Q30234637-2F308512-29DC-4154-A8EA-9B883B0BCC69 Q30375073-3F71154C-9500-426B-96E3-C1E721B306C0 Q30396642-91CAC359-6D4F-4A09-A1A8-153FAF2AD04E Q33619065-F739019F-B604-411C-9EA6-E33784876F3F Q33981963-9660FDE5-C4BF-4750-BE24-1D2CA68309DF Q34000122-749958AD-2109-4553-AD84-82234378E23C Q34510430-69E521D0-7603-40ED-986D-D72E96320807 Q34614260-518ACF8B-9989-4A02-9DD4-E8642CDE379B Q35192417-A528164E-ADAB-4633-982A-2610CD234430 Q35558539-E57C446B-E927-4BE8-BB3F-838595B3E648 Q35917496-FD19AE63-6005-422A-8414-D2D108DA7B30 Q35917501-BEC4FE9D-087C-4D04-A835-2217668FD41C Q36043199-83126E37-BDE3-4A40-AF4F-C532BBA32F6F Q36100545-BBE1CA23-FD3B-4411-9782-93B725C19590 Q36154869-283F63F7-E883-48BA-BCB8-04F3B9265E85 Q36404178-FE1470E7-0494-419D-84E1-DFBE4A2B3F3B Q36433538-A3CF2E79-039C-43B5-B4E6-AC239BCA771C Q36580268-CCB749C0-E2DB-4042-B4B5-E9C0F609999E Q36759754-8C1BDEA1-D5F5-45F0-A6D0-0D98B6511B27 Q36978876-F92E6EB9-1B4B-41A7-B115-B3397247890D Q36995725-DB91FCA7-6FAD-4584-B603-541AED74559D Q37627897-FB65B5DC-24A4-4122-91C8-9C50D23CD8DC Q38205274-A8B79186-836E-438A-8415-7320F9FDDBB9 Q38569831-521AF7BD-1B60-4E85-B0E7-BE7137A256D3 Q38615396-D840C108-12E3-4E1D-B2F6-150B5BF375D9 Q38728732-BFF4BB53-58CD-4424-854A-39BF9E4FF54F Q39129671-475BFFA6-4C80-433D-B944-90A4F37F3B8D Q39413473-22EA9261-D624-4438-A67C-CD2635573B51 Q40080155-41A66C66-C781-4007-9A98-FC68EC485530 Q40153269-3A39B3FE-13EA-4E95-870A-C7C1B00B0D8C Q55010162-199D332F-9B6E-431F-BA37-77D57BDA20EC

P2860

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

http://www.wikidata.org/entity/Q33434415

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

@ast

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

@en

type

label

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

@ast

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

@en

prefLabel

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

@ast

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

@en

P1433

Q33434415-46BDA4C3-85D9-44BF-9597-9B4ECD250388

P1476

Q33434415-87CAA8A2-753E-4649-89FE-F5AE4950410C

P2093

Q33434415-63196053-EBB6-4979-9509-54923BA4ED99

Q33434415-7AD7F01F-FB2B-40AD-AC5F-EE88D1962EF9

Q33434415-B0F0B113-6E03-469E-9531-5DF297B3EB97

Q33434415-B1A9754A-7CCE-4306-8862-109787104B57

Q33434415-DD5DF292-CA6A-4A9E-B7D3-D8C789B76B0B

P2860

Q33434415-0A329537-A613-4CED-B37F-0E5EB550EF63

Q33434415-0BCA4CE3-8115-4480-8ADC-D2FC85A812A3

Q33434415-14EC1C15-DC7F-4F27-AAEF-0218729D1BF8

Q33434415-16830442-C34C-427E-AEAD-A304C9EC3A9F

Q33434415-1D185120-0B7E-41B4-A135-2406C20431F9

Q33434415-1EE90557-CD0E-4EC1-AE8E-63F89E8F5C31

Q33434415-23FC2713-59F6-41FB-BD50-05373F2490BC

Q33434415-32BEFE3C-3770-4101-AE51-E43ABFE9E651

Q33434415-359D2846-2AD6-4036-AFC1-3BE5802F1463

Q33434415-639D9C19-6C8C-4C45-A3DF-5FD126DA9D79

P304

Q33434415-61EF8528-E78A-49E3-B925-73EB7D40490D

P31

Q33434415-5D62C55D-C68D-4DBC-B9F8-52166871193F

P356

Q33434415-4AF55834-A490-467E-85E7-001B238587FE

P407

Q33434415-61EA92EF-B2D1-460E-A7D4-80657550AD08

P433

Q33434415-F0E7524D-96B0-4FDA-AC6C-7A4CE179DFA8

P478

Q33434415-BA326936-B65D-494C-84A9-E51D407072E4

P50

Q33434415-5C757080-0D94-410C-BAAF-CCC4B1EE49ED

Q33434415-777FEF62-6950-48CA-9714-C486182A42F3

P577

Q33434415-7D32B4BF-31A9-46BE-B665-42B814516D12

P5875

Q33434415-F696C378-3D36-402B-99A2-C622D9245B73

P698

Q33434415-E53E2457-2234-42AB-B029-3A412C0083C0

P921

Q33434415-1302E50B-66E0-4DDB-8940-2BFD6DDF7736

Q33434415-91E98353-E17F-49B2-B73B-850CDB63CBB4

Q33434415-A153AC5C-FA08-4EEB-8453-D6FF3ADB7BA1

P932

Q33434415-AFC6AC0D-B99C-4E11-969D-C723FA28066D

P356

JOURNAL.PONE.0005308

P1433

P1476

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.

@en

P2093

James E Strong

http://www.w3.org/2001/XMLSchema#string

Jason S Richardson

http://www.w3.org/2001/XMLSchema#string

Kaylie N Tran

http://www.w3.org/2001/XMLSchema#string

Maria A Croyle

http://www.w3.org/2001/XMLSchema#string

Michel K Yao

http://www.w3.org/2001/XMLSchema#string

P2860

Efficient selection for high-expression transfectants with a novel eukaryotic vector

Development of a preventive vaccine for Ebola virus infection in primates

Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

Fruit bats as reservoirs of Ebola virus

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.

Hemorrhagic fever viruses as biological weapons: medical and public health management.

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.

Ebola virus: from discovery to vaccine.

'Green mice' as a source of ubiquitous green cells.

P304

e5308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0005308

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Gary P. Kobinger

P577

2009-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24356011

http://www.w3.org/2001/XMLSchema#string

P698

19390586

http://www.w3.org/2001/XMLSchema#string

P921

Vaccine against Ebola

P932

2669164

http://www.w3.org/2001/XMLSchema#string